Bristol Myers Squibb Company $BMY Shares Sold by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 26.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,014 shares of the biopharmaceutical company’s stock after selling 15,461 shares during the period. Capital Asset Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $2,603,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. Swiss RE Ltd. purchased a new stake in Bristol Myers Squibb during the fourth quarter worth about $25,000. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Bayban acquired a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb is continuing its collaboration with Arcus Biosciences on a kidney cancer trial, adding Arcus’s investigational drug casdatifan to Bristol Myers’ Phase 1/2 ROSETTA RCC-208 study. The update reinforces BMY’s pipeline activity in oncology, which could support long-term growth if the combination shows promise. Article Title
• Positive Sentiment: Several articles highlighted Bristol Myers Squibb as a value stock and a “trending” name, which can attract investor interest and reinforce the view that BMY may be attractive at its current valuation relative to peers. Article Title
• Positive Sentiment: Unusually heavy call-option activity suggests some traders are positioning for a rebound or a near-term move higher in Bristol Myers Squibb shares. Article Title
• Neutral Sentiment: Brisbane Myers Squibb was added to Russell 1000 Value Defensive and Defensive indexes while being removed from growth-oriented benchmarks. This mainly reflects a style reclassification rather than a direct business change, though it may influence fund flows and how investors view the stock. Article Title
• Negative Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for BMY to $6.31 from $6.32, a small cut that nevertheless signals modestly softer expectations for earnings growth. Article Title
• Negative Sentiment: Concerns about proposed Medicare drug-price negotiation changes remain a headwind for Bristol Myers Squibb, since policy pressure on drug pricing could affect future revenue and margins. Article Title

Analyst Ratings Changes

Several equities analysts have commented on BMY shares. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Bank of America cut their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Finally, Cantor Fitzgerald upped their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Trading Down 2.0%

Shares of NYSE:BMY opened at $56.46 on Thursday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company’s 50 day moving average is $56.95 and its two-hundred day moving average is $57.44. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market cap of $115.30 billion, a PE ratio of 15.86, a P/E/G ratio of 0.16 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.